OmniAb Inc. (OABI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, OmniAb Inc. (OABI) has a cash flow conversion efficiency ratio of 0.010x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.68 Million) by net assets ($260.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see OmniAb Inc. (OABI) total market value for the company's overall valuation and market capitalisation.
OmniAb Inc. - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how OmniAb Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
OmniAb Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OmniAb Inc. ranked by their cash flow conversion efficiency. Explore how high is OmniAb Inc.'s earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fastighetsbolaget Emilshus AB
ST:EMIL-B
|
0.019x |
|
ROX Resources Ltd
AU:RXL
|
-0.149x |
|
Konka Group Co Ltd
SHE:000016
|
0.068x |
|
SeaBird Exploration Plc
OL:SBX
|
0.148x |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
0.105x |
|
Nanfang Ventilator Co Ltd
SHE:300004
|
0.015x |
|
Energy Resources of Australia Ltd
AU:ERA
|
0.079x |
|
Sparebank 1 Ostfold Akershus
OL:SOAG
|
0.060x |
Annual Cash Flow Conversion Efficiency for OmniAb Inc. (2019–2025)
The table below shows the annual cash flow conversion efficiency of OmniAb Inc. from 2019 to 2025. View OmniAb Inc. (OABI) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $267.03 Million | $-36.45 Million | -0.137x | +1.00% |
| 2024-12-31 | $287.62 Million | $-39.66 Million | -0.138x | -1948.44% |
| 2023-12-31 | $314.58 Million | $2.35 Million | 0.007x | +171.00% |
| 2022-12-31 | $341.37 Million | $-3.59 Million | -0.011x | +56.59% |
| 2021-12-31 | $234.31 Million | $-5.67 Million | -0.024x | -257.55% |
| 2020-12-31 | $235.54 Million | $3.62 Million | 0.015x | +164.53% |
| 2019-12-31 | $218.19 Million | $-5.20 Million | -0.024x | -- |
About OmniAb Inc.
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partne… Read more